NHS Somerset is aiming to grow its referral rate through GP Community Pharmacist Consultation Service (GP CPCS) to between 4,000 to 6,000 patients a month.
Since June 2021 GPs in Somerset have successfully referred around 1,000 patients a month through the Somerset GP Community Pharmacist Consultation Service (GP CPCS)
Currently, 59 of NHS Somerset's 64 GP practices and all of Somerset's 102 community pharmacists are using the Somerset GP CPCS.
NHS Somerset found that providing the right training for GPs and for reception staff and practice managers was key to a smooth rollout and uptake of the service.
As was making sure the technology worked when making referrals from general practice to community pharmacists.
NHS Somerset is using software called Patient Access Connect, which seamlessly integrates with the EMIS Web GP system used in Somerset, to give practices a quick
and easy way to capture the patient information needed to deliver a referral.
The Health and Social Care Committee (HSCC) has undertaken an inquiry into prevention and has published its first report of the series which focuses on
vaccination.
It has announced ten workstreams that will form the basis of inquiry, of which vaccination is one.
HSCC said: "The UK has long been one of the world leaders on vaccination - one of the most successful and cost-effective preventative tools available. However,
if challenges around uptake and bureaucratic processes in clinical trial set-up are not addressed, there is a very real risk that the UK's position as a global
leader could be lost. This cannot be allowed to happen and in this report we set out some of the steps that we think will make a difference."
It recommended a more flexible delivery model making use of a wider range of healthcare professionals.
"The NHSE vaccination and immunisation strategy must have a strong focus on tackling practical challenges that limit vaccination access, make best use of a wider
array of professionals, empower local leaders to pursue ways of addressing uptake in their own areas, and to set out guidance and examples of best practice around
how voices other than NHSE can communicate important messaging around vaccination programmes," it suggested.
Within the last few weeks, at least six pharmacists have been subjected to interim order applications - either suspended or had significant restrictions
placed upon their registration pending a full 'Fitness to Practise' hearing into serious allegations being made about their prescribing practices, the Pharmacists'
Defence Association (PDA) has found.
It said that there has been a "dramatic increase in action being taken by the pharmacy regulator (GPhC) against pharmacist prescribers associated with certain types
of online prescribing services".
It has warned pharmacist prescribers who work for online pharmacies about the specific risks associated with remote prescribing using a questionnaire-based model,
typically with no direct prescriber/patient interaction.
Common features that underpin the allegations include the following: Overreliance on a patient questionnaire to inform clinical decision making; No patient/prescriber
interaction; Prescribing high risk medicines without adequate safeguards; Inadequate systems and processes leading to inappropriate prescribing; Very high volumes
of prescriptions being authorised in short periods of time; and Prescribers/patient relationship established via an unregulated online portal.
Dr Amanda Doyle has been appointed as NHS England as director of primary and community care.
Prior to her new role, Amanda had joined NHS England and NHS Improvement as North West Regional Director on 2 August 2021 and previously she was the Chief
Clinical Officer for West Lancashire Clinical Commissioning Group (CCG), Blackpool CCG and Fylde and Wyre CCG.
Amanda was also the Integrated Care System Lead for Lancashire and South Cumbria, leading a large health and care transformation programme across the patch.
She has been a GP for more than 20 years, practising in a large practice in a deprived area of Blackpool, which, in addition to primary medical services, provides a range of urgent care services for patients across the Fylde Coast.
Amanda was the Co-Chair of NHS Clinical Commissioners from 2013 to 2018.
She was Senior Responsible Officer for the primary care component of the Long Term Plan and was involved in the leadership of the health inequalities, prevention and personalisation elements.
The Royal Pharmaceutical Society (RPS) has published a new professional guidance for prescribing practice on Monday (June 6) which it says will be "for the
benefit of all independent prescribers across the UK".
Based on collaboration with multi-professional stakeholders, the document is a guidance tool for prescribers wanting to expand their prescribing scope of practice.
Commissioned by the Welsh government, the document was developed through an expert group with representatives from many healthcare professions, including from Higher Education institutions, professional bodies, regulatory bodies, the National Institute for Health and Care Excellence, NHS Education for Scotland, Health Education
and Improvement Wales, and representatives from hospital, community and GP practice.
RPS president Claire Anderson said: "It's fantastic to see the growth in prescribing, both across the profession and more widely, to improve patient care.
The Royal Pharmaceutical Society (RPS) has published its new 'Core Advanced Pharmacist Curriculum' to enable professional development towards advanced pharmacist
practice.
This follows an intensive programme of work undertaken in collaboration with a wide range of UK stakeholders, the society said today (June 27) in a statement.
The Curriculum will equip pharmacists with advanced leadership, education, and research capabilities which are essential to support, lead and advance the profession
through transformative change so it continues to meet evolving patient and service requirements.
The RPS Core Advanced Curriculum provides the blueprint to develop such individuals by articulating a UK entry-level standard to advanced pharmacist practice,
relevant to all patient-focussed pharmacist roles and aligned to multi-professional definitions of advanced practice.
This curriculum completes the core RPS post-registration curricula, creating a seamless post-registration professional development continuum modelled around five
common domains- Person-centred care and collaboration; Professional practice; Leadership and management; Education; and Research.
The Fitness-to-Practise Committee of the General Pharmaceutical Council has issued a three-month suspension to Mohammed Roohul Haque (Reg No: 2226084), a
locum pharmacist, due to incidents of workplace sexual misconduct.
According to the determination document issued by the regulatory body, Haque undertook the position of a locum pharmacist at Hollowood Chemists on July 12. It was
during this period that he encountered the dispenser (referred to as the "complainant"), a 40-year-old co-worker at the pharmacy, for the first instance. Following
this initial meeting, he proceeded to engage in making explicit sexual comments.
During the lunch break of the pharmacy's second dispenser, Haque asked the dispenser, who had lodged the complaint, to review photographs displayed on his mobile
phone, depicting renovations being carried out at his residence. The initial images focused on the ongoing renovation activities. However, he later switched to
displaying a full-screen photograph of his erect penis, the document said.
Despite the fact that the dispenser promptly distanced herself, Haque persisted in discussing the photograph with her. He went so far as to apologise, and even
asked if she had managed to closely observe the picture.
Essential Pharma, an international speciality pharma group, has procured an establishment and manufacturing licences in Switzerland and Malta.
Following a successful inspection by Swissmedic, the company has been granted an establishment licence in Switzerland, which will allow the company to significantly
enhance its supply chain efficiency for a wide range of important medicinal products. It will apply to transactions for both finished and unfinished pharmaceuticals,
allowing importing, exporting, wholesaling and trading abroad.
Essential Pharma has also received a manufacturing and importation authorisation (MIA) in Malta, following a successful Good Manufacturing Practice (GMP) inspection
by the Malta Medicines Authority.
The MIA will allow the company to import medicinal products into the European Union where manufacturing has taken place in a third country. This will allow greater
flexibility in how the business manages the flow of medicines across its territories.
These approvals strengthen the company's geographical expansion, improve its operational efficiencies, and enhance its offering as a global business partner. They
will also provide new strategic opportunities for the company and will play a fundamental role in driving value creation through functional improvements to scale
and productivity.
The Home Affairs Committee has called upon the government to revise its current drug policy, moving away from the exclusive 'abstinence only' approach towards
a more practical strategy that highlights harm reduction. The HAC's recommendations also include the introduction of a national naloxone programme in England, with
community pharmacies playing a central role in facilitating access.
The committee published its comprehensive report on August 31, with key recommendations, including the 'urgent' reclassification of psychedelic drugs for therapeutic
research; a pilot safe consumption facility program (long resisted by the Westminster Government despite Scottish lobbying); and enhanced provision and research on
cannabis-based medicinal products (CBPMs).
The report urged the establishment of a national naloxone programme in England, aligning with devolved nations. It also highlighted the role of community pharmacists
and peer initiatives for effective distribution and administration. Furthermore, the report emphasises enhanced naloxone distribution for prison leavers. Naloxone is
a medication capable of rapidly reversing heroin or methadone overdoses, potentially saving lives.
Susan Rienow, UK Managing Director and Country President of Pfizer is all set to take up her role as President of the Association of the British Pharmaceutical
Industry (ABPI).
The association had announced her appointment in March. Last year in September she was appointed as the vice-president of ABPI.
In her new role, she will oversee the ABPI, the ABPI Board, and the ABPI's Code of Practice, which is administered by the Prescription Medicines Code of Practice
Authority (PMCPA).
Susan takes up the Presidency as negotiations begin for a new Voluntary Scheme for branded medicines pricing between the government, NHS England and the ABPI.
All parties are looking to secure a new agreement that will help improve patient outcomes, support a healthier population and a financially sustainable NHS, while
also supporting economic growth for the UK.
The National Pharmacy Association (NPA) has asked the Secretary of State for Health and Social Care to convene a 'medicines supply taskforce', following weeks
of problems with antibiotics supplies.
The NPA's chief executive Mark Lyonette wrote a letter to Steve Barclay this week. It cited the precedent of the HRT Taskforce which this summer brought together
representatives from across the supply chain after months of supply problems affecting women.
"We strongly believe that this situation calls for a similar response from the government. It is imperative that we resolve this supply situation urgently and
therefore we request that you convene a Medicines Supply Taskforce, with all the relevant stakeholders in the supply chain, to urgently discuss and agree practical
solutions to address the disruptions to the supply of medicines. HRT and antibiotics are the most visible examples of a wider problem with medicines supply
which needs to be addressed."
NPA board members Olivier Picard and Reena Barai were among the stakeholders joining meetings convened by the HRT Taskforce this summer.
The Royal Pharmaceutical Society (RPS) on Wednesday announced that it is spearheading a new project, which aims to delve into the root causes of the
growing challenge of medicines shortages across the United Kingdom and provide solutions to mitigate its impact on patients and pharmacy practice.
A newly formed advisory group, chaired by RPS Fellow Dr. Bruce Warner, is set to convene later this month. The group will have experts from primary and secondary
care, patient advocacy groups, the pharmaceutical industry, suppliers, regulatory bodies, governmental representatives, and NHS officials.
The group aims to formulate a robust report to provide expert thought leadership and support for the wider debate on UK policy. Their work will be informed by a
thorough literature review, stakeholder interviews, online RPS member events, and patient stories.
The Association of the British Pharmaceutical Industry (ABPI) today released a new guidance to pharmaceutical companies using Disclosure UK which it said will boost transparency in the relationships between healthcare professionals, other relevant decision-makers and the industry.
The guidance encourages companies to use 'Legitimate Interests' as their lawful basis for processing individual's data, in order to increase the number of named healthcare professionals and other individuals on Disclosure UK, the database showing the payments and benefits in kind made by the pharmaceutical industry to doctors,nurses and other health professionals and organizations.
"I'm pleased the ABPI is launching this new guidance which will boost patient safety and public confidence in our healthcare professionals," Patient Safety and Primary Care Minister Maria Caulfield commented.
To help transform care for patients, the Royal Pharmaceutical Society (RPS) is calling on the General Pharmaceutical Council (GPhC) to remove the two-year post qualification wait for pharmacists before they are allowed to start their independent prescriber training.
RPS proposes that entry to training should be based on whether pharmacists can evidence the necessary skills, knowledge, and experience to undertake the training, and not the length of time a pharmacist has been on the register.
RPS president Claire Anderson said: "We've campaigned strongly for better use of pharmacist independent prescribers, who are becoming essential to multi professional teams in all health care settings.
"We want to ensure pharmacy remains an attractive career and has parity with the other professions. Pharmacist prescribing is now moving from being a skill only associated with advanced specialist levels of practice to a more generalist scope, providing a workforce that's more flexible with a shared set of capabilities.
The Royal Pharmaceutical Society (RPS) has cautioned that measures to protect people against Covid-19 must be stepped up in the wake of discovery of the new variant, B.1.1.529.
It has urged members of the public to practice 'hands, face, space and ventilation' protection measures which have become less used in the last few months.
RPS director of pharmacy Robbie Turner said that though it was too early to conclude about the transmissibility or resistance of the new variant to current vaccines, quick action should be taken to protect the public.
"Each one of us must take the necessary precautions of wearing a mask in higher risk situations, maintaining social distancing wherever possible, ensuring there's appropriate ventilation indoors when meeting others and washing our hands regularly."
Encouraging people to take Covid vaccine, he said, it "is still our best defence against this virus".
Titan PMR has been accredited by the NHS to provide electronic prescription services (EPS) to dispensing doctors.
Over 1,000 of these doctors, who provide a vital service to almost 10 million people in rural communities, can now offer their patients the same level of benefits
and efficiencies that electronic prescriptions and Titan PMR have brought to pharmacies around the UK.
These features will also increase efficiency for dispensing doctors, who will reduce dispensing errors and improve organisation, increasing their capacity while
enjoying the ability to integrate with other technologies.
After a full year of testing, including six months of compliance testing at a practice in Cumbria, the new accreditation for Titan also has potential to help the
NHS fulfil its target of all prescriptions being issued electronically.
Currently written paper prescriptions from dispensing doctors account for around seven per cent of the total prescriptions in England - around 6.5 million each month.
"Until now dispensing doctor surgeries have basically been in the digital dark ages when it comes to dispensing medicines," said Tariq Muhammad, a tech entrepreneur
and CEO of Bristol-based Invatech Health, which developed Titan PMR.
Are you interested in a career helping others improve their overall health and wellbeing through nutrition? Becoming a nutritionist is an excellent way to
make a positive impact on the lives of your patients. Nutritionists are experts in understanding how food affects our bodies, so they can provide advice on healthy
eating habits, dietary requirements for certain medical conditions, and more.
However, it takes more than just interest to become a successful nutritionist - there are specific qualifications and experience that you need to have before you
can practice as one. In this blog post, we will look at what it entails so that you can start planning your journey toward becoming a certified professional
nutritionist. We'll cover the education needed for certification, any licensing or registration requirements necessary for practicing in different states or
countries, what kind of skillset potential employers might be looking for when hiring nutritional professionals, and finally some tips on gaining practical
experience while working towards full accreditation. So if you are serious about becoming a nutritionist, let's get started!
FORMAL EDUCATION REQUIREMENTS
The first step towards becoming a certified professional nutritionist is often completing an accredited program in either dietetics or nutrition. A Bachelor's degree
in Nutrition Science, Food Science, and Human Nutrition or Dietetics would be the minimum qualification for entry-level positions as a nutritionist. However, there
are many advanced courses available that can take you further in this field such as Master of Nutrition programs and postgraduate degrees.
"Our main concerns are that the use of what they call an asynchronous supply, where the prescriber neither sees nor talks to the patient at the time they
issue the prescription, does lay itself open to perhaps people getting hold of medication that they shouldn't," the Head of Policy, PDA said.
The Pharmacists' Defence Association (PDA) engages in a critical conversation on BBC Radio 4's Woman's Hour, shedding light on the online prescribing of weight
loss drugs and advocating for safer practices.
The PDA's spokesperson, Head of Policy Alima Batchelor, emphasised the importance of adhering to professional guidelines to ensure patient safety and mitigate
regulatory concerns.
During the feature, the PDA highlighted the complexities and risks associated with online supply chains, stressing the necessity for direct clinical consultations
and pharmacist involvement in medication management.
""There are guidelines and advice about verification within the DiCE guidance, but it doesn't go quite far enough for us. We are concerned when patients decline
to allow the online prescriber to advise their GP of what they're taking," Batchelor highlighted.
The Medicines and Healthcare products Regulatory Agency (MHRA) and the Committees of Advertising Practice (CAP) have issued a joint enforcement notice about
the 'illegal' advertising of Kenalog injections on digital platforms.
The notice warns all organisations offering Kenalog as a 'hay fever treatment' to stop advertising it in any of their social media or website advertising.
"Kenalog is a prescription-only medicine (POM), which must not be directly or indirectly advertised to the public. Kenalog is not licensed for the treatment of hay
fever in the UK, although it is offered by some beauty and aesthetics clinics, under the personal responsibility of an individual prescriber, and advertised widely
on social media," said MHRA.
"Now, advertisers must ensure that all references to Kenalog in the text, images or emojis on social media are removed, as well as commonly-used descriptive phrases
for the jab such as 'hay fever injection' or hay fever jab' or any account names, testimonials or memes by 29 August 2022."
After this date, the CAP's compliance team will remove non-compliant ads using targeted software and those who continue to promote it may be referred to the MHRA for
further enforcement action.
The Department of Health and Social Care (DHSC) and NHS England last month issued a "safety critical" national patient safety alert, warning about
the UK-wide shortage of a life-saving drug used to treat patients with chronic breathing issues.
NHS trusts, health authorities, ambulance services, GP practices, private healthcare providers, and community pharmacy contractors were informed that
salbutamol 2.5mg and 5mg nebuliser liquid unit dose vials are in short supply, with the latter likely to remain "out of stock" until mid-April 2024.
As per the alert, the shortage of the drug resulted from a combination of manufacturing issues, leading to heightened demand for alternative suppliers.
It was mentioned that while terbutaline, salbutamol with ipratropium, and ipratropium nebuliser liquids remained available, they could't meet the increased demand.